Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03150576
Title Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer (PARTNER)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cambridge University Hospitals NHS Foundation Trust

Her2-receptor negative breast cancer


Carboplatin + Paclitaxel

Carboplatin + Olaparib + Paclitaxel

Age Groups: senior | adult | child
Covered Countries

No variant requirements are available.